CHF stem cell therapy success, page-2

Yankee, you are absolutely right in that it is better to ignore those who write without reason and criticise without evidence. In my previous messages, I advised it is best not to comment as it is a waste of time and only encourages unnecessary exchanges. I have stayed clear and will wait until we receive more announcements from MSB. Julie Meldrum sent me some reports from the likes of Bell Potter, Macquarie Wealth Management and Lodge Partners and while Macquarie has maintained the view that the Phase 3 CHF trial as high risk, the other two were positive. The analyses were made with facts available and there is still the area of the unknown now which which will come to light shortly. My discussions with MSB has revealed that there is a great deal of confidence among those involved in the trials and this will be known in the not so distant future. So I chose to wait.